ArticleMolecular neurodegeneration2007
Lack of alpha-synuclein increases amyloid plaque accumulation in a transgenic mouse model of Alzheimer's disease.
Article in Molecular neurodegeneration, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 33 citations in OpenAlex.
- Early Amyloid Formation and Neuroinflammatory Response in a Bigenic Mouse Model Expressing Human α-Synuclein and Aβ.Parkinson's disease · 2026Article
- Exploring α-Syn's Functions Through Ablation Models: Physiological and Pathological Implications.Cellular and molecular neurobiology · 2025Review
- Impact of 6-OHDA injection and microtrauma in the ratHistology and histopathology · 2025Article
- α-Synuclein Aggregation Is Triggered by Oligomeric Amyloid-β 42 via Heterogeneous Primary Nucleation.Journal of the American Chemical Society · 2023Article
- Distinct Aβ pathology in the olfactory bulb and olfactory deficits in a mouse model of Aβ and α-syn co-pathology.Brain pathology (Zurich, Switzerland) · 2022Article
- The existence of Aβ strains and their potential for driving phenotypic heterogeneity in Alzheimer's disease.Acta neuropathologica · 2021Review
- Soluble endogenous oligomeric α-synuclein species in neurodegenerative diseases: Expression, spreading, and cross-talk.Journal of Parkinson's disease · 2020Review
- Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities.Translational neurodegeneration · 2019Review
- Aβ Seeding as a Tool to Study Cerebral Amyloidosis and Associated Pathology.Frontiers in molecular neuroscience · 2019Review
- The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer's disease.Acta neuropathologica communications · 2018Article
- Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons.Acta neuropathologica · 2018Article
- The effects of apolipoprotein E genotype, α-synuclein deficiency, and sex on brain synaptic and Alzheimer's disease-related pathology.Alzheimer's & dementia (Amsterdam, Netherlands) · 2018Article
- Monomeric and fibrillar α-synuclein exert opposite effects on the catalytic cycle that promotes the proliferation of Aβ42 aggregates.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- α-Synuclein increases β-amyloid secretion by promoting β-/γ-secretase processing of APP.PloS one · 2017Article
- Icariin reduces α-synuclein over-expression by promoting α-synuclein degradation.Age (Dordrecht, Netherlands) · 2015Article
- Inhibition of amyloid-β plaque formation by α-synuclein.Nature medicine · 2015Article
- What we can learn from animal models about cerebral multi-morbidity.Alzheimer's research & therapy · 2015Article
- Aggregation of αSynuclein promotes progressive in vivo neurotoxicity in adult rat dopaminergic neurons.Acta neuropathologica · 2012Article
- Alpha-synuclein deficiency leads to increased glyoxalase I expression and glycation stress.Cellular and molecular life sciences : CMLS · 2011Article
- Overexpression of SOD-2 reduces hippocampal superoxide and prevents memory deficits in a mouse model of Alzheimer's disease.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Alpha-synuclein is a small soluble, cytosolic protein which associates with vesicular membranes. It is a component of intracellular Lewy bodies present in Parkinson's disease and a subset of Alzheimer's disease (AD). In addition, early studies identified a fragment of alpha-synuclein in the amyloid plaques of AD patients. Hypothesizing that alpha-synuclein might modify the AD pathogenic process, we crossed the Tg2576 strain of APP transgenic mice onto an alpha-synuclein knockout background to determine the effects of alpha-synuclein on Abeta production and plaque deposition. We found that alpha-synuclein deficiency does not affect the Abeta levels, nor does it alter the age of onset of plaque pathology. To our surprise, however, loss of alpha-synuclein leads to a significant increase in plaque load in all areas of the forebrain at 18 months of age. This is associated with an increase in another synaptic protein, synaptophysin. We thus conclude that alpha-synuclein is not involved in seeding of the plaques, but rather suppresses the progression of plaque pathology at advanced stages.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.